AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23082385 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 17
Study 23082385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 20609851 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental motivational beliefs (role construction)
Number of subjects: 0
Study 20609851 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental motivational beliefs (efficacy)
Number of subjects: 0
Study 18501068 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine in conjunction with radiation therapy
Number of subjects: 0
Study 18501068 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU) based chemotherapy
Number of subjects: 0
Study 15643914 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills intervention
Number of subjects: 45
Study 15643914 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study 12794466 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap skin donor site (group I)
Number of subjects: 38
Study 12794466 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral thigh donor site (group II)
Number of subjects: 38
Study 10492099 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal TRH 400 microg every eight hours for four doses
Number of subjects: 225
Study 10492099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 10492099 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal TRH
Number of subjects: 225
Study 8601364 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ursodeoxycholic acid (UDCA) per day (N = 14)
Number of subjects: 58
Study 8601364 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin per day (N = 14)
Number of subjects: 58
Study 8601364 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (N = 15)
Number of subjects: 58
Study 8601364 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control, N = 15)
Number of subjects: 58
Study 1902253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous ketamine
Number of subjects: 0
Study 1902253 — intervention group
Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 0
Study 30991248 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) at a dosage of 2400 mg/day
Number of subjects: 24
Study 30991248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29898192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 16 sessions
Number of subjects: 0
Study 26778719 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-Hz ipsilesional rTMS
Number of subjects: 40
Study 26778719 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz contralesional rTMS
Number of subjects: 40
Study 26778719 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study 26778719 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-Hz rTMS
Number of subjects: 40
Study 24636501 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion training
Number of subjects: 0
Study 24636501 — intervention group
Group type: COMPARATOR
Intervention: Attention (placebo) control
Number of subjects: 0
Study 24636501 — intervention group
Group type: COMPARATOR
Intervention: No-training control
Number of subjects: 0
Study 22490391 — intervention group
Group type: EXPERIMENTAL
Intervention: BioP-plus
Number of subjects: 100
Study 22490391 — intervention group
Group type: EXPERIMENTAL
Intervention: PXL-8
Number of subjects: 100
Study 19845788 — intervention group
Group type: EXPERIMENTAL
Intervention: True manipulation
Number of subjects: 52
Study 19845788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 18035796 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC-driven MDI
Number of subjects: 419
Study 18035796 — intervention group
Group type: EXPERIMENTAL
Intervention: non-CFC (HFA) MDI
Number of subjects: 419
Study 18035796 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol dry powder inhaler (DPI)
Number of subjects: 419
Study 18035796 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 419
Study 18035796 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of inhalers
Number of subjects: 419
Study 16135832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 512
Study 16135832 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 percent dextran 70 (a colloid)
Number of subjects: 512
Study 16135832 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 percent hydroxyethyl starch (a colloid)
Number of subjects: 512
Study 16135832 — intervention group
Group type: COMPARATOR
Intervention: All fluid-treatment groups
Number of subjects: 512
Study 11806986 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 10 microg/kg subcutaneous daily for 5 days
Number of subjects: 8
Study 11806986 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim mobilization
Number of subjects: 8
Study 11806986 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSCs collected from SCT
Number of subjects: 8
Study 11806986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation in 5% dimethyl sulfoxide/6% pentastarch
Number of subjects: 8
Study 10430523 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg body weight i.v.)
Number of subjects: 50
Study 10430523 — intervention group
Group type: COMPARATOR
Intervention: Control (no methylprednisolone)
Number of subjects: 50
Study 7589378 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term inhaled corticosteroids (200 micrograms b.i.d.) for 4 weeks
Number of subjects: 32
Study 7589378 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term inhaled corticosteroids (100-1000 micrograms b.i.d.) for less than 6 months
Number of subjects: 32
Study 7589378 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 32
Study 1981784 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine collected overnight, corrected for creatinine
Number of subjects: 32
Study 1981784 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine collected overnight, expressed as microgram albumin/mg creatinine
Number of subjects: 32
Study 1981784 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine samples collected overnight, corrected for creatinine
Number of subjects: 32
Study 7298846 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDC) 750 mg/d
Number of subjects: 63
Study 7298846 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDC) 375 mg/d
Number of subjects: 63
Study 7298846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 31625952 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education (n=33)
Number of subjects: 57
Study 31625952 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual, n=24)
Number of subjects: 57
Study 28685960 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator (SCE) therapy
Number of subjects: 0
Study 28685960 — intervention group
Group type: EXPERIMENTAL
Intervention: SCE therapy
Number of subjects: 0
Study 27097857 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg intranasal midazolam sedation
Number of subjects: 40
Study 27097857 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg sublingual midazolam sedation
Number of subjects: 40
Study 24313543 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised dietary intervention (increased consumption of fruits, vegetables, and whole grains)
Number of subjects: 51
Study 24313543 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised dietary intervention
Number of subjects: 51
Study 24313543 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal clinical treatment without customised dietary advice)
Number of subjects: 51
Study 22327053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention with larger month-to-month weight losses in year 1
Number of subjects: 2438
Study 22327053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention with sustained weight loss during the first year
Number of subjects: 2438
Study 22327053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention with larger monthly weight loss during year 1
Number of subjects: 2438
Study 19534616 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-breathing exercises
Number of subjects: 60
Study 19534616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-breathing exercises
Number of subjects: 60
Study 19534616 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 16855765 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of tadalafil taken as needed (maximum once daily)
Number of subjects: 0
Study 16855765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12697798 — intervention group
Group type: EXPERIMENTAL
Intervention: External hip protector
Number of subjects: 561
Study 12697798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hip protector)
Number of subjects: 561
Study 12697798 — intervention group
Group type: EXPERIMENTAL
Intervention: External hip protector (compliant participants)
Number of subjects: 561
Study 10805064 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxsalen (CYP2A6 inhibitor)
Number of subjects: 27
Study 10805064 — intervention group
Group type: EXPERIMENTAL
Intervention: Troleandomycin (CYP3A4 inhibitor)
Number of subjects: 27
Study 10805064 — intervention group
Group type: COMPARATOR
Intervention: Control (no inhibitor)
Number of subjects: 27
Study 8877655 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minocycline hydrochloride-gel
Number of subjects: 20
Study 8877655 — intervention group
Group type: COMPARATOR
Intervention: Placebo-gel
Number of subjects: 20
Study 8877655 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minocycline hydrochloride-gel and Placebo-gel
Number of subjects: 20
Study 1817947 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive care program (information on oral hygiene, fluoridation and healthy nutrition, instructions and training) in group 1
Number of subjects: 200
Study 1817947 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of fluoride tablets for babies planned by group 1
Number of subjects: 200
Study 1817947 — intervention group
Group type: COMPARATOR
Intervention: Use of fluoride tablets for babies planned by group 2
Number of subjects: 200
Study 6407598 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation as aspartate hydrochloride 15 mmol/day for six months
Number of subjects: 20
Study 6407598 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 20
Study 31242936 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF) on post-operative day 1 (POD1)
Number of subjects: 200
Study 31242936 — intervention group
Group type: COMPARATOR
Intervention: Delayed oral feeding (DOF) on post-operative day 4 (POD4)
Number of subjects: 200
Study 31242936 — intervention group
Group type: EXPERIMENTAL
Intervention: EOF group
Number of subjects: 200
Study 31242936 — intervention group
Group type: COMPARATOR
Intervention: DOF group
Number of subjects: 200
Study 29025481 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondent's external stigma (RES) scale
Number of subjects: 882
Study 29025481 — intervention group
Group type: EXPERIMENTAL
Intervention: Others' external stigma (OES) scale
Number of subjects: 882
Study 29025481 — intervention group
Group type: EXPERIMENTAL
Intervention: All four stigma scales
Number of subjects: 882
Study 25420946 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist-delivered diabetes support program (5 months, 5 follow-up visits, 5 phone calls)
Number of subjects: 101
Study 25420946 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist-delivered diabetes support program
Number of subjects: 101
Study 25420946 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 101
Study 23435801 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback (BIO)
Number of subjects: 18
Study 23435801 — intervention group
Group type: COMPARATOR
Intervention: Comparative group (COM)
Number of subjects: 18
Study 22046722 — intervention group
Group type: EXPERIMENTAL
Intervention: virtual-physical fidelity training
Number of subjects: 0
Study 22046722 — intervention group
Group type: EXPERIMENTAL
Intervention: cognitive fidelity training
Number of subjects: 0
Study 22046722 — intervention group
Group type: EXPERIMENTAL
Intervention: real-world training
Number of subjects: 0
Study 22046722 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 0
Study 19277796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics for 2 days followed by oral antibiotics for 7 days
Number of subjects: 80
Study 19277796 — intervention group
Group type: COMPARATOR
Intervention: Surgery (control group)
Number of subjects: 80
Study 16420755 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNalpha‐2a
Number of subjects: 60
Study 16420755 — intervention group
Group type: COMPARATOR
Intervention: CIFNalpha‐2a
Number of subjects: 60
Study 16420755 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNalpha‐2a (genotype 1)
Number of subjects: 60
Study 16420755 — intervention group
Group type: COMPARATOR
Intervention: CIFNalpha‐2a (genotype 1)
Number of subjects: 60
Study 15785008 — intervention group
Group type: EXPERIMENTAL
Intervention: Green coffee bean extract (GCE) 140 mg/day for 4 months
Number of subjects: 20
Study 15785008 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink for 4 months
Number of subjects: 20
Study 11320110 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 7
Study 11320110 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonexercise)
Number of subjects: 7
Study 10209405 — intervention group
Group type: EXPERIMENTAL
Intervention: Atkinson tubes
Number of subjects: 87
Study 10209405 — intervention group
Group type: COMPARATOR
Intervention: Self-expanding metal stents
Number of subjects: 87
Study 8165852 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa with 25 micrograms PT
Number of subjects: 308
Study 8165852 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa with 8 micrograms PT
Number of subjects: 308
Study 8165852 — intervention group
Group type: COMPARATOR
Intervention: DTPw (whole-cell pertussis DTP vaccine)
Number of subjects: 308
Study 3421452 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic intubation
Number of subjects: 0
Study 3421452 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope intubation
Number of subjects: 0
Study 28418191 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinlida
Number of subjects: 192
Study 26656958 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 45
Study 26656958 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections with glargine (MDI/G)
Number of subjects: 45
Study 26333503 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentration of contrast agent (270 mgI/mL of iodixanol)
Number of subjects: 180
Study 26333503 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration of contrast agent (320 mgI/mL of iodixanol)
Number of subjects: 180
Study 26333503 — intervention group
Group type: COMPARATOR
Intervention: Scan condition A (120 kV, 300 mA)
Number of subjects: 180
Study 26333503 — intervention group
Group type: COMPARATOR
Intervention: Scan condition B (100 kV, 400 mA)
Number of subjects: 180
Study 26333503 — intervention group
Group type: COMPARATOR
Intervention: Scan condition C (100 kV, 300 mA)
Number of subjects: 180
Study 23439163 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap-filling approach for continuous glucose monitoring (CGM) data
Number of subjects: 0
Study 20519679 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential ACT (four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel)
Number of subjects: 5351
Study 20519679 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin-docetaxel (four cycles of doxorubicin and docetaxel)
Number of subjects: 5351
Study 20519679 — intervention group
Group type: COMPARATOR
Intervention: Concurrent ACT (four cycles of doxorubicin, cyclophosphamide, and docetaxel)
Number of subjects: 5351
Study 20519679 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential ACT
Number of subjects: 5351
Study 20519679 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin-docetaxel
Number of subjects: 5351
Study 20519679 — intervention group
Group type: COMPARATOR
Intervention: Concurrent ACT
Number of subjects: 5351
Study 20519679 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 5351
Study 18442577 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 sympathectomy
Number of subjects: 232
Study 18442577 — intervention group
Group type: COMPARATOR
Intervention: T2-4 sympathectomy
Number of subjects: 232
Study 18442577 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 232
Study 16600674 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental study of the median nerve
Number of subjects: 267
Study 16600674 — intervention group
Group type: EXPERIMENTAL
Intervention: Median-to-radial comparative test
Number of subjects: 267
Study 16600674 — intervention group
Group type: EXPERIMENTAL
Intervention: Median-to-ulnar comparative test
Number of subjects: 267
Study 16600674 — intervention group
Group type: COMPARATOR
Intervention: Normal limits derived from controls
Number of subjects: 267
Study 12780910 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anterior resection and anastomosis
Number of subjects: 15978
Study 12780910 — intervention group
Group type: COMPARATOR
Intervention: Abdomino-perineal resection
Number of subjects: 15978
Study 10705222 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (200-600 mg/day)
Number of subjects: 48
Study 10705222 — intervention group
Group type: COMPARATOR
Intervention: Control (no theophylline treatment)
Number of subjects: 48
Study 9172875 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin impregnated curtains
Number of subjects: 501
Study 9172875 — intervention group
Group type: COMPARATOR
Intervention: Nonimpregnated curtains (Control)
Number of subjects: 501
Study 8465772 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 600 mg/day for 10 days, followed by 400 mg/day for 10 days, then 200 mg/day for 2 months
Number of subjects: 63
Study 8465772 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 63
Study 8465772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 3805473 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 13
Study 3805473 — intervention group
Group type: COMPARATOR
Intervention: Cold steel surgery and electrocautery
Number of subjects: 13
Study 29935528 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group (received bupivacaine + 5 mcg dexmedetomidine)
Number of subjects: 90
Study 29935528 — intervention group
Group type: COMPARATOR
Intervention: Control group (received bupivacaine + the same volume of saline)
Number of subjects: 90
Study 29935528 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Number of subjects: 90
Study 29935528 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 27924459 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg
Number of subjects: 171
Study 27924459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 24343824 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 330
Study 24343824 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 330
Study 24343824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of magnesium sulfate and albuterol
Number of subjects: 330
Study 22398963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT) for 12-14 weeks
Number of subjects: 523
Study 19320802 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental and periodontal treatments plus oral hygiene education
Number of subjects: 58
Study 19320802 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment approach with only oral hygiene education
Number of subjects: 58
Study 18097211 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational program regarding influenza vaccine
Number of subjects: 92
Study 15249718 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 50 mg/m² on days 1, 8, and 15 plus carboplatin (dose escalation starting at AUC 5 mg x min/ml to AUC 6)
Number of subjects: 16
Study 15249718 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose level 1 (MTD) of irinotecan and carboplatin
Number of subjects: 16
Study 12733372 — intervention group
Group type: EXPERIMENTAL
Intervention: DS 10 mg q.n. for 8 weeks (Group A)
Number of subjects: 160
Study 12733372 — intervention group
Group type: EXPERIMENTAL
Intervention: Zocor 10 mg q.n. for 8 weeks (Group B)
Number of subjects: 160
Study 12733372 — intervention group
Group type: COMPARATOR
Intervention: DS 10 mg q.n. for 8 weeks (Group C)
Number of subjects: 160
Study 9853855 — intervention group
Group type: COMPARATOR
Intervention: Standard intrauterine insemination (IUI)
Number of subjects: 96
Study 9853855 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion (FSP)
Number of subjects: 96
Study 9853855 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate/HMG
Number of subjects: 96
Study 9853855 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate only
Number of subjects: 96
Study 8009591 — intervention group
Group type: EXPERIMENTAL
Intervention: BMA 031 (50 mg administered intravenously on the day of, as well as 2 and 4 days after transplantation)
Number of subjects: 36
Study 8009591 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 36
Study 8009591 — intervention group
Group type: EXPERIMENTAL
Intervention: BMA 031
Number of subjects: 36
Study 2623005 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 5.5 mg/kg
Number of subjects: 0
Study 2623005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0